YWYu-Quan Wei

Yu-Quan Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu-Quan Wei has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2011
      • Vol. 42  (5) , 594-8

    [The molecular mechanism of extravasation in mouse melanoma lung metastasis model].

    by Lu-Ming Pang, Cheng-Jian Zhao, Yu-Wei Zhao, Zhi-Mian Li, Han-Shuo Yang, Yu-Quan Wei

    To study molecular mechanisms underlying the extravasation of mice melanoma cells during lung metastasis. B16-RED melanoma cell line was established which stably express the red fluorescent protein. B16-RED cells were compared with B16 cells in ability of proliferation and lung metastasis. A mouse lung metastasis model was established with B16-RED melanoma cells. FITC-dextran was injected i.v. and CD31 indirect immunoflourescence (IIF) staining was made to identify the location of the tumor cells and the time of tumor cell extravasation. Finally, at 48 hours post cell injection, the lung and a normal lung were removed and used for 32K mice microarray analysis. B16-RED was consistent with B16 in cell shape and ability of proliferation and lung metastasis. 52.7% of B16-RED melanoma cells completed the extravasation within 48 hours in mouse lung metastasis model. Many important signal pathways were involved during lung metastasis, including leukocyte transendothelial migration, MAPK signaling pathway, neuroactive ligand-receptor interaction, focal adhesion, cytokine-cytokine receptor interaction, regulation of actin cytoskeleton, axon guidance, calcium signaling pathway, tight junction, etc. The extravasation during metastasis is a complex and multiple-steps process, in which many important signal pathways in host tissues were involved.

  • Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3‐kinase/Akt pathway during anti‐angiogenesis therapy

    by Yu Wei Zhao, Lu Jin, Zhi Mian Li, Cheng Jian Zhao, Yu Quan Wei, Han Shuo Yang

    Anti-angiogenesis has been a promising strategy for cancer therapy. However, many signal pathways are activated during anti-angiogenic treatment to counteract the therapeutic efficacy. Among these pathways, evidence has directly pointed to the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway, whose activation resulted in tolerance to the absence of nutrients and oxygen when tumor angiogenesis has been inhibited. In the present study, we investigated the effects of blocking activation of the PI3K/Akt pathway on cell survival in vitro and tumor growth in vivo during anti-angiogenesis therapy. In modeled microenvironments in vitro, we observed that the phosphorylation of Akt in tumor cells was increased gradually in the absence of serum and oxygen in a time-dependent manner. The specific inhibitors of PI3K inhibited the proliferation of tumor cells in a dose-dependent manner in vitro. Moreover, inhibition was enhanced gradually with increased serum deprivation and/or hypoxia. In a mouse tumor model, we found the phosphorylation of Akt obviously increased following anti-angiogenic therapy using plasmids encoding soluble vascular endothelial growth factor receptor-2, but significantly reduced after treatment with LY294002. Consequently, the combinational treatment exhibited better antitumor effects compared with single treatments, presenting larger necrosis-like areas, more apoptotic cells, less microvessel density and less phosphorylated Akt in tumors. These results suggest that blocking activation of the PI3K/Akt pathway during anti-angiogenesis therapy could enhance antitumor efficacy. Thus, targeting the PI3K/Akt pathway might be a promising strategy to reverse tumor resistance to anti-angiogenesis therapy.


  • Open Access

    Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model

    by Xian-Ping Liu, Sheng-Tao Zhou, Xing-Yi Li, Xian-Cheng Chen, Xia Zhao, Zhi-Yong Qian, Li-Na Zhou, Zhi-Yong Li, Yu-Mei Wang, Qian Zhong, et al.

    Background: Camptothecin (CPT) has recently attracted increasing attention as a promising anticancer agent for a variety of tumors. But the clinical application is largely hampered by its extreme water insolubility and unpredictable side effect. It is essential to establish an efficient and safe protocol for the administration of CPT versus melanoma. Methods: Camptothecin was encapsulated with N-trimethyl chitosan (CPT-TMC) through microprecipitation and sonication. Its inhibition effect on B16-F10 cell proliferation and induction of apoptosis was evaluated by MTT assay and flow cytometric analysis in vitro. The anti-tumor activity of CPT-TMC was evaluated in C57BL/6 mice bearing B16-F10 melanoma. Tumor volume, tumor weight and survival time were recorded. Assessment of apoptotic cells within tumor tissue was performed by TUNEL assay. Antiangiogenesis and antiproliferation effects of CPT-TMC in vivo were conducted via CD31 and PCNA immunohistochemistry, respectively. Results: CPT-TMC efficiently inhibited B16-F10 cells proliferation and increased apoptosis in vitro. Experiment group showed significant inhibition compared with free CPT-treated group (81.3% vs. 56.9%) in the growth of B16-F10 melanoma xenografts and prolonged the survival time of the treated mice (P < 0.05). Decreased cell proliferation, increased tumor apoptosis as well as a reduction in angiogenesis were observed. Conclusions: Our data suggest that N-trimethyl chitosan-encapsulated camptothecin is superior to free CPT by overcoming its insolubility and finally raises the potential of its application in melanoma therapy.


  • Open Access

    Enhancement of cisplatin sensitivity in lewis lung carcinoma by liposome-mediated delivery of a survivin mutant

    by Dan-Dan Yu, Chun-Ting Wang, Hua-Shan Shi, Zhi-Yong Li, Li Pan, Qing-Zhong Yuan, Fei Leng, Yuan Wen, Xiang Chen, Yu-Quan Wei

    Background: A high concentration of cisplatin (CDDP) induces apoptosis in many tumor cell lines. CDDP has been administered by infusion to avoid severe toxicity. Recently, it has been reported that changes in survivin expression or function may lead to tumor sensitization to chemical and physical agents. The aim of this study was to determine whether a dominant-negative mouse survivin mutant could enhance the anti-tumor activity of CDDP. Methods: A plasmid encoding the phosphorylation-defective dominant-negative mouse survivin threonine 34→alanine mutant (survivin T34A) complexed to a DOTAP-chol liposome (Lip-mS) was administered with or without CDDP in Lewis Lung Carcinoma (LLC) cells and in mice bearing LLC tumors, and the effects on apoptosis, tumor growth and angiogenesis were assessed. Data were analyzed using one-way analysis of variance(ANOVA), and a value of P < 0.05 was considered to be statistically significant. Results: LLC cells treated with a combination of Lip-mS and CDDP displayed increased apoptosis compared with those treated with Lip-mS or CDDP alone. In mice bearing LLC tumors and treated with intravenous injections of Lip-mS and/or CDDP, combination treatment significantly reduced the mean tumor volume compared with either treatment alone. Moreover, the antitumor effect of Lip-mS combined with CDDP was greater than their anticipated additive effects. Conclusion: These data suggest that the dominant-negative survivin mutant, survivin T34A, sensitized LLC cells to chemotherapy of CDDP. The synergistic antitumor activity of the combination treatment may in part result from an increase in the apoptosis of tumor cells, inhibition of tumor angiogenesis and induction of a tumor-protective immune response.


  • Open Access

    Enhanced tumor radiosensitivity by a survivin dominant-negative mutant

    by Qing-Zhong Yuan, Chun-Ting Wang, Yong-Qiu Mao, Peng Zhang, Hua-Shan Shi, Zhi-Yong Li, L I Pan, Dan-Dan Yu, Fei Leng, Xiang Chen, et al.

    Radiosensitivity of tumors is due to a complex interaction of various factors, it has been reported that survivin also acts as a constitutive and inducible radioresistance factor in a panel of tumor cells and approaches designed to inhibit survivin expression or function may lead to tumor sensitisation to chemical and physical agents. Previously, we found that the plasmid encoding the phosphorylation-defective mouse survivin threonine 34-->alanine mutant complexed to DOTAP-chol liposome (Lip-mS) can suppress murine primary breast carcinoma. However, little is known regarding the biological effect of Lip-mS combined with radiation. The present study was designed to determine whether Lip-mS could enhance the anti-tumor activity of radiation. The Lewis Lung Carcinoma (LLC) cells treated with a combination of Lip-mS and radiation displayed apparently increased apoptosis compared with those treated with Lip-mS or radiation alone. Mice bearing LLC tumors were treated with intravenous injections of Lip-mS and radiation, the combined treatment significantly reduced mean tumor volume compared with either treatment alone. Moreover, the anti-tumor effect of Lip-mS combined with radiation was greater than their additive effect when compared with the expected effect of the combined treatment. These data suggest that inhibition of survivin using a dominant-negative mutant, survivin T34A, could sensitize LLC cells to radiation efficiently and the synergistic anti-tumor activity may in part result from increasing the apoptosis of tumor cells, inhibiting tumor angiogenesis and inducing a tumor-protective immune response in the combined treatment.


  • Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1

    by Wei, Quan Liu, Xin-Yu Zhao, Rui-Zhen Bai, Shu-Fang Liang, Chun-Lai Nie, Zhu Yuan, Chun-Ting Wang, Yang Wu, Li-Juan Chen, et al.

    Down-regulated in renal cell carcinoma gene (DRR1) is one of the candidate tumor suppressor genes (TSGs) on human 3p21.1. This study was performed to validate the expression status of DRR1 gene in cancer cells and the expression pattern of the protein in clinical specimens of human lung cancer and to examine its potential as a molecular target for treatment of lung cancer in vivo. DRR1 expression was analyzed in 7 human lung cancer cell lines. DRR1 protein expression was also examined in clinical non-small cell lung cancer (NSCLC) specimens. Furthermore, effects of DRR1 re-expression on A549 cells in vitro and A549 xenograft tumors in nude mice were evaluated. Loss of DRR1 mRNA expression was detected in 6 of the 7 human cancer cell lines, the exception was the renal cancer cell line OS-RC-2. DRR1 protein expression was absent in 15 of 20 (75%) human NSCLC specimens by immunostaining. Transfection of DRR1 gene into DRR1-negative-expressing A549 cells resulted in significant cell growth suppression and apoptosis. Plasmids containing DRR1 cDNA complexed with DOTAP:Chol liposomes were administered intravenously via tail vein to nude mice bearing A549 xenograft tumors resulting in tumor growth inhibition and elevation of apoptosis compared with the controls. DRR1 is a potent growth suppressor of NSCLC, acting through apoptosis pathway in vivo and it may be a potential therapeutic gene for human lung cancer.


    • 1 September 2009
      • Vol. 40  (5) , 803-6

    [Inhibition of tumour cells with hepatitis B virus x (HBx) gene adenoviral vector in vivo].

    by Hui-Min Lü, Ping Cheng, Qing-Qing Tang, Ping Chen, Xing-Chen Peng, Yu-Hua Li, Yan-Jun Wen, Yu-Quan Wei

    To investigate the inhibitory effects of the hepatitis B virus x protein (HBx protein) on tumor in vivo. H22 cells were infected with Ad-eGFP to detect infection efficiency of adenovirus. The BALB/c mouse model of malignant ascites was established by implanting H22 cell intraperitoneally into the animal, Ad-HBx, Ad-null or NS were administered intraperitoneally in BALB/c mice separately to detect HBx expression in H22 cells and effects of HBx on inhibition on proliferation of H22 cells. High efficiency of Ad in infecting H22 cells in vitro was observed. HBx protein was expressed in H22 cells after intraperitoneal injection of Ad-HBx. The effect of Ad-HBx on inhibition of the peritoneal capillary permeability and the ascites accumulation (P<0.05); on reduction of the number of red cells and tumor cells counted in malignant ascites (P<0.05), and on inhibition of tumor cell life cycle (the G2/M arrest) in malignant ascites were identified by flow cytometric analysis. HBx protein can be expressed in tumour cells and can inhibit the proliferation of tumour cells in vivo, and this might be a new potential treatment for malignant ascites.


  • Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity

    by Chang-Yang Gong, Shuai Shi, Xin-Yun Peng, Bing Kan, Li Yang, Mei-Juan Huang, Feng Luo, Xia Zhao, Yu-Quan Wei, Zhi-Yong Qian

    • 1 July 2009
      • Vol. 40  (4) , 569-74

    [Construction and identification of eukaryotic co-expression plasmid carrying FUS1 and recombinant human IL-12 genes and its effection on apoptosis of A549 cells].

    by Dong-Mei Zhang, Han-Shuo Yang, Wen Zhu, Zhi-Hua Feng, Hong-Xin Deng, Yu-Quan Wei

    To construct a eukaryotic co-expression plasmid containing FUS1 and IL-12, and to investigate the influence of the recombinant plasmid on the cultured human lung cancer cell line A549. RT-PCR was applied to amplify FUS1 from MRC-5 cell, the cDNA fragment of IL-12 was derived from pORF-hIL-12 by PCR, FUS1 cDNA fragment and IL-12 cDNA fragment were inserted into the multiple cloning sites of pVITRO2 to generate the eukaryotic co-expression plasmid pVITRO2-FUS1-IL-12. The recombinant plasmid was confirmed by restriction endonuclease treatment and sequenceing and transfected into A549 cells. The expression of genes in pVITRO2-FUS1-IL-12 were identified by RT-PCR, ELISA and Western blot. The function of pVITRO2-FUS1-IL-12 inducing the apoptosis of lung cancer was identified by Hoechst33258 and flow cytometry. The restriction endonuclease digestion and sequencing suggested that co-expression vector pVITRO2-FUS1-IL-12 was constructed successfully, the expression of FUS1 and IL-12 could be detected in A549 cells. The expressions of the two genes in pVITRO2 were not affected. The A549 cells transfected with pVITRO2-FUS1-IL-12 exhibited significant cell apoptosis. The recombinant eukaryotic expression vector pVITRO2-FUS1-IL-12 was constructed and expressed in eukaryotic cell successfully, which would contribute to a novel and effective treatment strategies for combined gene therapy for lung cancer.


  • Open Access

    Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma

    by Li-Ping Yang, Ping Cheng, Xing-Chen Peng, Hua-Shan Shi, Wei-Hong He, Feng-Yu Cui, Shun-Tao Luo, Yu-Quan Wei, Li Yang

    Angiogenesis plays an important role in tumor growth, invasion, and eventually metastasis. Antiangiogenic strategies have been proven to be a promising approach for clinical therapy for a variety of tumors. As a potent inhibitor of tumor angiogenesis, pigment epithelium-derived factor (PEDF) has recently been studied and used as an anticancer agent in several tumor models.